Skip to main content

Table 1 Demographic and clinical data by group

From: Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

VariableLevelTNBC (n = 130)MBC (n = 44)Totalp value
Age at initial diagnosisMean (SD)54.6 (12.8)55.4 (13.9)54.8 (13.0) [n = 174]0.7495
RaceWhite108 (83.1%)40 (90.9%)148 (85.1%)0.2451
Black14 (10.8%)4 (9.1%)18 (10.3%)
Other8 (6.2%)0 (0.0%)8 (4.6%)
Hispanic ethnicityYes3 (2.3%)0 (0.0%)3 (1.8%)1.0000
Positive nodesYes60 (46.2%)13 (29.5%)73 (42.0%)0.0765
StageI16 (12.3%)6 (13.6%)22 (12.6%)0.9812
II96 (73.8%)32 (72.7%)128 (73.6%)
III15 (11.5%)5 (11.4%)20 (11.5%)
IV3 (2.3%)1 (2.3%)4 (2.3%)
ER statusPositive0 (0.0%)4 (9.1%)4 (2.3%)0.0037
Negative130 (100.0%)40 (90.9%)170 (97.7%)
PR statusPositive0 (0.0%)4 (9.1%)4 (2.3%)0.0037
Negative130 (100.0%)40 (90.9%)170 (97.7%)
HER2 statusPositive0 (0.0%)1 (2.3%)1 (0.6%)0.0146
Negative130 (100.0%)43 (97.7%)170 (98.3%)
  1. p values from a two-sample t test for continuous variables and a Fisher’s exact test for categorical variables. Abbreviations: ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; MBC = metaplastic breast cancer; PR = progesterone receptor; SD = standard deviation; TNBC = triple-negative breast cancer